CaMKII: The molecular villain that aggravates cardiovascular disease (Review)

Zhang,Peiying

doi:10.3892/etm.2017.4034

CaMKII: The molecular villain that aggravates cardiovascular disease (Review)

Authors:
- Peiying Zhang
View Affiliations

Affiliations: Department of Cardiology, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu 221009, P.R. China
Published online on: January 11, 2017 https://doi.org/10.3892/etm.2017.4034
Pages: 815-820
Copyright: © Zhang . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pathological remodeling of the myocardium is an integral part of the events that lead to heart failure (HF), which involves altered gene expression, disturbed signaling pathways and altered Ca2+ homeostasis and the players involved in this process. Of particular interest is the chronic activation of Ca2+/calmodulin‑dependent protein kinase II (CaMKII) isoforms in heart, which further aggravate the injury to myocardium. Expression and activity of CaMKII have been found to be elevated in various conditions of stressed myocardium and in different heart diseases in both animal models as well as heart patients. CaMKII is a signaling molecule that regulates many cellular pathways by phosphorylating several proteins involved in excitation‑contraction coupling and relaxation events in heart, cardiomyocyte apoptosis, transcriptional activation of genes related to cardiac hypertrophy, inflammation, and arrhythmias. CaMKII is activated by reactive oxygen species (ROS), which are elevated under conditions of ischemia‑reperfusion injury and in a cyclical manner, CaMKII in turn elevates ROS production. Both ROS and activated CaMKII increase Ca‑induced Ca release from sarcoplasmic reticulum, which leads to cardiomyocyte membrane depolarization and arrhythmias. These CaMKII‑mediated changes in heart ultimately culminate in dysfunctional myocardium and HF. Genetic studies in animal models clearly demonstrated that inactivation of CaMKII is protective against a variety of stress induced cardiac dysfunctions. Despite significant leaps in understanding the structural details of CaMKII, which is a very complicated and multimeric modular protein, currently there is no specific and potent inhibitor of this enzyme, that can be developed for therapeutic purposes.

View Figures

View References

1	Nabel EG and Braunwald E: A tale of coronary artery disease and myocardial infarction. N Engl J Med. 366:54–63. 2012. View Article : Google Scholar : PubMed/NCBI
2	Daniels L, Bell JR, Delbridge LM, McDonald FJ, Lamberts RR and Erickson JR: The role of CaMKII in diabetic heart dysfunction. Heart Fail Rev. 20:589–600. 2015. View Article : Google Scholar : PubMed/NCBI
3	Mathers CD and Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3:e4422006. View Article : Google Scholar : PubMed/NCBI
4	Joseph SM, Cedars AM, Ewald GA, Geltman EM and Mann DL: Acute decompensated heart failure: Contemporary medical management. Tex Heart Inst J. 36:510–520. 2009.PubMed/NCBI
5	McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, et al: ESC Committee for Practice Guidelines: Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the heart failure association (hfa) of the esc. Eur Heart J. 33:1787–1847. 2012. View Article : Google Scholar : PubMed/NCBI
6	Hill JA and Olson EN: Cardiac plasticity. N Engl J Med. 358:1370–1380. 2008. View Article : Google Scholar : PubMed/NCBI
7	Bers DM: Cardiac sarcoplasmic reticulum calcium leak: Basis and roles in cardiac dysfunction. Annu Rev Physiol. 76:107–127. 2014. View Article : Google Scholar : PubMed/NCBI
8	Cho GW, Altamirano F and Hill JA: Chronic heart failure: Ca(2+), catabolism, and catastrophic cell death. Biochim Biophys Acta. 1862:763–777. 2016. View Article : Google Scholar : PubMed/NCBI
9	van Oort RJ, Brown JH and Westenbrink BD: CaMKII confirms its promise in ischaemic heart disease. Eur J Heart Fail. 16:1268–1269. 2014. View Article : Google Scholar : PubMed/NCBI
10	Grandi E, Edwards AG, Herren AW and Bers DM: CaMKII comes of age in cardiac health and disease. Front Pharmacol. 5:1542014. View Article : Google Scholar : PubMed/NCBI
11	Bers DM: Ca²⁺-calmodulin-dependent protein kinase II regulation of cardiac excitation-transcription coupling. Heart Rhythm. 8:1101–1104. 2011. View Article : Google Scholar : PubMed/NCBI
12	Couchonnal LF and Anderson ME: The role of calmodulin kinase II in myocardial physiology and disease. Physiology (Bethesda). 23:151–159. 2008. View Article : Google Scholar : PubMed/NCBI
13	Luczak ED and Anderson ME: CaMKII oxidative activation and the pathogenesis of cardiac disease. J Mol Cell Cardiol. 73:112–116. 2014. View Article : Google Scholar : PubMed/NCBI
14	Bell JR, Vila-Petroff M and Delbridge LM: CaMKII-dependent responses to ischemia and reperfusion challenges in the heart. Front Pharmacol. 5:962014. View Article : Google Scholar : PubMed/NCBI
15	Grimm M, Ling H and Brown JH: Crossing signals: Relationships between β-adrenergic stimulation and CaMKII activation. Heart Rhythm. 8:1296–1298. 2011. View Article : Google Scholar : PubMed/NCBI
16	Zhao Z, Fefelova N, Shanmugam M, Bishara P, Babu GJ and Xie LH: Angiotensin II induces afterdepolarizations via reactive oxygen species and calmodulin kinase II signaling. J Mol Cell Cardiol. 50:128–136. 2011. View Article : Google Scholar : PubMed/NCBI
17	Swaminathan PD, Purohit A, Hund TJ and Anderson ME: Calmodulin-dependent protein kinase II: Linking heart failure and arrhythmias. Circ Res. 110:1661–1677. 2012. View Article : Google Scholar : PubMed/NCBI
18	Mishra S, Gray CB, Miyamoto S, Bers DM and Brown JH: Location matters: Clarifying the concept of nuclear and cytosolic CaMKII subtypes. Circ Res. 109:1354–1362. 2011. View Article : Google Scholar : PubMed/NCBI
19	Hoelz A, Nairn AC and Kuriyan J: Crystal structure of a tetradecameric assembly of the association domain of Ca²⁺/calmodulin-dependent kinase II. Mol Cell. 11:1241–1251. 2003. View Article : Google Scholar : PubMed/NCBI
20	Anderson ME, Brown JH and Bers DM: CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol. 51:468–473. 2011. View Article : Google Scholar : PubMed/NCBI
21	Bers DM and Morotti S: Ca(2+) current facilitation is CaMKII-dependent and has arrhythmogenic consequences. Front Pharmacol. 5:1442014. View Article : Google Scholar : PubMed/NCBI
22	Mustroph J, Maier LS and Wagner S: CaMKII regulation of cardiac K channels. Front Pharmacol. 5:202014. View Article : Google Scholar : PubMed/NCBI
23	Sierra A, Zhu Z, Sapay N, Sharotri V, Kline CF, Luczak ED, Subbotina E, Sivaprasadarao A, Snyder PM, Mohler PJ, et al: Regulation of cardiac ATP-sensitive potassium channel surface expression by calcium/calmodulin-dependent protein kinase II. J Biol Chem. 288:1568–1581. 2013. View Article : Google Scholar : PubMed/NCBI
24	Sellers ZM, De Arcangelis V, Xiang Y and Best PM: Cardiomyocytes with disrupted CFTR function require CaMKII and Ca(2+)-activated Cl(−) channel activity to maintain contraction rate. J Physiol. 588:2417–2429. 2010. View Article : Google Scholar : PubMed/NCBI
25	Braun AP and Schulman H: The multifunctional calcium/calmodulin-dependent protein kinase: From form to function. Annu Rev Physiol. 57:417–445. 1995. View Article : Google Scholar : PubMed/NCBI
26	Dupont G, Houart G and De Koninck P: Sensitivity of CaM kinase II to the frequency of Ca²⁺ oscillations: A simple model. Cell Calcium. 34:485–497. 2003. View Article : Google Scholar : PubMed/NCBI
27	Respress JL, van Oort RJ, Li N, Rolim N, Dixit SS, deAlmeida A, Voigt N, Lawrence WS, Skapura DG, Skårdal K, et al: Role of RyR2 phosphorylation at S2814 during heart failure progression. Circ Res. 110:1474–1483. 2012. View Article : Google Scholar : PubMed/NCBI
28	Anderson ME: Sticky fingers: CaMKII finds a home on another ion channel. Circ Res. 104:712–714. 2009. View Article : Google Scholar : PubMed/NCBI
29	Makara MA, Curran J, Little SC, Musa H, Polina I, Smith SA, Wright PJ, Unudurthi SD, Snyder J, Bennett V, et al: Ankyrin-G coordinates intercalated disc signaling platform to regulate cardiac excitability in vivo. Circ Res. 115:929–938. 2014. View Article : Google Scholar : PubMed/NCBI
30	Sossalla S, Fluschnik N, Schotola H, Ort KR, Neef S, Schulte T, Wittköpper K, Renner A, Schmitto JD, Gummert J, et al: Inhibition of elevated Ca²⁺/calmodulin-dependent protein kinase II improves contractility in human failing myocardium. Circ Res. 107:1150–1161. 2010. View Article : Google Scholar : PubMed/NCBI
31	Maier LS: CaMKIIdelta overexpression in hypertrophy and heart failure: Cellular consequences for excitation-contraction coupling. Braz J Med Biol Res. 38:1293–1302. 2005. View Article : Google Scholar : PubMed/NCBI
32	Weinreuter M, Kreusser MM, Beckendorf J, Schreiter FC, Leuschner F, Lehmann LH, Hofmann KP, Rostosky JS, Diemert N, Xu C, et al: CaM kinase II mediates maladaptive post-infarct remodeling and pro-inflammatory chemoattractant signaling but not acute myocardial ischemia/reperfusion injury. EMBO Mol Med. 6:1231–1245. 2014. View Article : Google Scholar : PubMed/NCBI
33	Mattiazzi A, Bassani RA, Escobar AL, Palomeque J, Valverde CA, Petroff M Vila and Bers DM: Chasing cardiac physiology and pathology down the CaMKII cascade. Am J Physiol Heart Circ Physiol. 308:H1177–H1191. 2015. View Article : Google Scholar : PubMed/NCBI
34	Zhang T, Maier LS, Dalton ND, Miyamoto S, Ross J Jr, Bers DM and Brown JH: The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res. 92:912–919. 2003. View Article : Google Scholar : PubMed/NCBI
35	Backs J, Backs T, Neef S, Kreusser MM, Lehmann LH, Patrick DM, Grueter CE, Qi X, Richardson JA, Hill JA, et al: The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci USA. 106:2342–2347. 2009. View Article : Google Scholar : PubMed/NCBI
36	van Oort RJ, McCauley MD, Dixit SS, Pereira L, Yang Y, Respress JL, Wang Q, De Almeida AC, Skapura DG, Anderson ME, et al: Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure. Circulation. 122:2669–2679. 2010. View Article : Google Scholar : PubMed/NCBI
37	Kreusser MM, Lehmann LH, Keranov S, Hoting MO, Oehl U, Kohlhaas M, Reil JC, Neumann K, Schneider MD, Hill JA, et al: Cardiac CaM kinase II genes δ and γ contribute to adverse remodeling but redundantly inhibit calcineurin-induced myocardial hypertrophy. Circulation. 130:1262–1273. 2014. View Article : Google Scholar : PubMed/NCBI
38	Wu Y and Anderson ME: CaMKII in sinoatrial node physiology and dysfunction. Front Pharmacol. 5:482014. View Article : Google Scholar : PubMed/NCBI
39	DeGrande S, Nixon D, Koval O, Curran JW, Wright P, Wang Q, Kashef F, Chiang D, Li N, Wehrens XH, et al: CaMKII inhibition rescues proarrhythmic phenotypes in the model of human ankyrin-B syndrome. Heart Rhythm. 9:2034–2041. 2012. View Article : Google Scholar : PubMed/NCBI
40	Liu N, Ruan Y, Denegri M, Bachetti T, Li Y, Colombi B, Napolitano C, Coetzee WA and Priori SG: Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+/−) mice with catecholaminergic polymorphic ventricular tachycardia. J Mol Cell Cardiol. 50:214–222. 2011. View Article : Google Scholar : PubMed/NCBI
41	Erickson JR, Joiner ML, Guan X, Kutschke W, Yang J, Oddis CV, Bartlett RK, Lowe JS, O'Donnell SE, Aykin-Burns N, et al: A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell. 133:462–474. 2008. View Article : Google Scholar : PubMed/NCBI
42	Chao LH, Pellicena P, Deindl S, Barclay LA, Schulman H and Kuriyan J: Intersubunit capture of regulatory segments is a component of cooperative CaMKII activation. Nat Struct Mol Biol. 17:264–272. 2010. View Article : Google Scholar : PubMed/NCBI
43	Rueda JO Velez, Palomeque J and Mattiazzi A: Early apoptosis in different models of cardiac hypertrophy induced by high renin-angiotensin system activity involves CaMKII. J Appl Physiol 1985. 112:2110–2120. 2012. View Article : Google Scholar : PubMed/NCBI
44	Luo M, Guan X, Luczak ED, Lang D, Kutschke W, Gao Z, Yang J, Glynn P, Sossalla S, Swaminathan PD, et al: Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. J Clin Invest. 123:1262–1274. 2013. View Article : Google Scholar : PubMed/NCBI
45	Singh MV, Swaminathan PD, Luczak ED, Kutschke W, Weiss RM and Anderson ME: MyD88 mediated inflammatory signaling leads to CaMKII oxidation, cardiac hypertrophy and death after myocardial infarction. J Mol Cell Cardiol. 52:1135–1144. 2012. View Article : Google Scholar : PubMed/NCBI
46	Mollova MY, Katus HA and Backs J: Regulation of CaMKII signaling in cardiovascular disease. Front Pharmacol. 6:1782015. View Article : Google Scholar : PubMed/NCBI
47	Pellicena P and Schulman H: CaMKII inhibitors: From research tools to therapeutic agents. Front Pharmacol. 5:212014. View Article : Google Scholar : PubMed/NCBI
48	Zhang R, Khoo MS, Wu Y, Yang Y, Grueter CE, Ni G, Price EE Jr, Thiel W, Guatimosim S, Song LS, et al: Calmodulin kinase II inhibition protects against structural heart disease. Nat Med. 11:409–417. 2005. View Article : Google Scholar : PubMed/NCBI
49	Cipolletta E, Rusciano MR, Maione AS, Santulli G, Sorriento D, Del Giudice C, Ciccarelli M, Franco A, Crola C, Campiglia P, et al: Targeting the CaMKII/ERK interaction in the heart prevents cardiac hypertrophy. PLoS One. 10:e01304772015. View Article : Google Scholar : PubMed/NCBI
50	Erickson JR, Pereira L, Wang L, Han G, Ferguson A, Dao K, Copeland RJ, Despa F, Hart GW, Ripplinger CM, et al: Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature. 502:372–376. 2013. View Article : Google Scholar : PubMed/NCBI
51	Stølen TO, Høydal MA, Kemi OJ, Catalucci D, Ceci M, Aasum E, Larsen T, Rolim N, Condorelli G, Smith GL, et al: Interval training normalizes cardiomyocyte function, diastolic Ca²⁺ control, and SR Ca²⁺ release synchronicity in a mouse model of diabetic cardiomyopathy. Circ Res. 105:527–536. 2009. View Article : Google Scholar : PubMed/NCBI
52	Bennett CE, Johnsen VL, Shearer J and Belke DD: Exercise training mitigates aberrant cardiac protein O-GlcNAcylation in streptozotocin-induced diabetic mice. Life Sci. 92:657–663. 2013. View Article : Google Scholar : PubMed/NCBI